Abliva

• PIPE of 429,714,285 new shares at a subscription price of SEK 0.35 per share, generating gross proceeds of c. SEK 150m
• Fully Guaranteed Rights Issue of 146,547,924 new shares at a subscription price of SEK 0.35 per share (10% discount to closing price), generating gross proceeds of c. SEK 50m for which the subscription period will run from June 10th, until and including June 27th 2022
• The transaction is truly transformative for Abliva as it will more than double their market cap. The Company intends to use the net proceeds to fund the commencement and progression of a potentially registrational Phase 2/3 study for KL1333 in mitochondrial disease and to support the preparation of Abliva’s second asset, NV354, for the clinic
• Via the PIPE, Abliva welcomes new specialist biotech and institutional investors, including IP Group, a FTSE250 London-based science & technology investor with particular expertise in the global biotechnology industry, existing specialist life science investor Hadean Ventures, and OPF, a Norwegian institutional investor, along other international institutional investors
• Besides the transformative PIPE, this marks the second transaction where Kempen & Co has assisted a Life Sciences company with a so-called “Guaranteed Rights Issue”, thereby creating deal certainty for its clients even in very difficult market circumstances, and underpinning our ambition to serve our clients with a wide variety of tailormade financing structures

Abliva is a publicly listed Swedish biotech focused on the development of medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺/NADH modulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development.

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma 
• Co-Manager in the USD 700 million Capital Increase by argenx
• Sole Block Placing Agent in the placement of 1.4m Molecular Partners shares
• Joint Bookrunner in the USD 127 million Nasdaq IPO of Forbion European Acquisition Corp
• Co-Lead Manager in the USD 115 million Nasdaq Initial Public Offering by IO Biotech
• Lead manager in the USD 127 million Global Offering of Merus
• Joint Global Coordinator and Joint Bookrunner in the €31.5 million Euronext IPO by MaaT Pharma
• Co-Manager in the USD 460 million Capital Increase by Ascendis Pharma
• Joint Bookrunner in the SEK 324 million Capital Increase by Calliditas Therapeutics
• Joint Global Coordinator & Joint Bookrunner in the SEK 380 million Capital Increase by Xbrane Biopharma
• Joint Global Coordinator in the €34.1m Capital Increase by Transgene
• Joint Global Coordinator & Joint Bookrunner in the SEK 141 million Capital Increase by Immunicum
• Lead Manager in the USD 63.8 million Nasdaq Initial Public Offering by Molecular Partners
• Joint Bookrunner in the SEK 301 million Capital Increase by Q-linea